All In Biotech

Drug Trial Radar · NCT00339014

Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity

A Dose Parallel, Randomized, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of Multiple Regimens of the Combination of Zonisamide CR Plus Bupropion SR in the Treatment of Subjects With Uncomplicated Obesity

Last checked: Nov 20, 2026Latest source record: Apr 22, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 611 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

611

Actual

Start

May 2006

Primary completion

Aug 2007

Study completion Aug 2007

Sponsor

Lead sponsor
Orexigen Therapeutics, IncIndustry
Sponsor type
Industry
First posted
Jun 20, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine which of seven combinations of Zonisamide CR and Bupropion SR gives the best weight loss and is safe and well tolerated for the treatment of obesity not associated with the complications of obesity such as diabetes. In a previous study, the combination of zonisamide and bupropion SR was shown to be effective for weight loss compared to either zonisamide, bupropion SR alone or placebo. It is thought that by adjusting the doses of each drug, giving zonisamide in a controlled release (CR) form and increasing the doses more slowly, more weight loss and less side effects can be attained.

Conditions

  • Obesity

Interventions

  • Zonisamide CR and Bupropion SRDrug

    Zonisamide SR and Bupropion SR

  • PlaceboOther

    Identical placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. % change in total body weight as measured between baseline and week 24 (ITT-LOCF analysis)Time frame: Baseline to week 24

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • SelfCenter, PC

    Fairhope, Alabama

  • UCLA Center for Human Nutrition

    Los Angeles, California

  • Scripps Clinic Del Mar

    San Diego, California

  • Center for Human Nutrition University of Colorado Health Sciences Center

    Denver, Colorado

  • George Washington University Weight Management Program

    Washington D.C., District of Columbia

  • CSRA Partners in Health, Inc

    Augusta, Georgia

  • Springfield Diabetes and Endocrine Center

    Springfield, Illinois

  • Pennington Biomedical Research Center

    Baton Rouge, Louisiana

  • Nutrition and Weight Mangement Center Boston Medical Center

    Boston, Massachusetts

  • Center for Nutrition and Metabolic Diseases

    Reno, Nevada

  • Comprehensive Weight Control Program

    New York, New York

  • Center for Nutrition and Preventive Medicine

    Charlotte, North Carolina

  • MUSC Weight Mnagement Center

    Charleston, South Carolina

  • The Cooper Institute

    Dallas, Texas

  • Baylor Endocrine Center

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.